Transcriptome based individualized therapy of refractory pediatric sarcomas

• Verfasst von: Weidenbusch, Bushra [VerfasserIn]
• Verfasst von: Witt, Olaf [VerfasserIn]
• Titel: Transcriptome based individualized therapy of refractory pediatric sarcomas
• Titelzusatz: feasibility, tolerability and efficacy
• Verf.angabe: Bushra Weidenbusch, Günther H.S. Richter, Marie Sophie Kesper, Monika Guggemoos, Katja Gall, Carolin Prexler, Ilya Kazantsev, Alexandra Sipol, Lars Lindner, Michaela Nathrath, Olaf Witt, Katja Specht, Frigga Beitinger, Carolin Knebel, Stuart Hosie, Rüdiger von Eisenhardt-Rothe, Wilko Weichert, Irene Teichert-von Luettichau and Stefan Burdach
• E-Jahr: 2018
• Jahr: April 17, 2018
• Umfang: 14 S.
• Fussnoten: Gesehen am 02.07.2019
• Titel Quelle: Enthalten in: OncoTarget
• Ort Quelle: [S.l.] : Impact Journals LLC, 2010
• Jahr Quelle: 2018
• Band/Heft Quelle: 9(2018), 29, Seite 20747-20760
• ISSN Quelle: 1949-2553
• DOI: doi:10.18632/oncotarget.25087
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: adolescents and young adults
• Sach-SW: expression profiling
• Sach-SW: pediatric cancer
• Sach-SW: sarcoma
• Sach-SW: targeted therapy
• K10plus-PPN: 1668306506

Abstract

Survival rates of pediatric sarcoma patients stagnated during the last two decades, especially in adolescents and young adults (AYAs). Targeted therapies offer new options in refractory cases. Gene expression profiling provides a robust method to characterize the transcriptome of each patient's tumor and guide the choice of therapy. Twenty patients with refractory pediatric sarcomas (age 8-35 years) were assessed with array profiling: ten had Ewing sarcoma, five osteosarcoma, and five soft tissue sarcoma. Overexpressed genes and deregulated pathways were identified as actionable targets and an individualized combination of targeted therapies was recommended. Disease status, survival, adverse events (AEs), and quality of life (QOL) were assessed in patients receiving targeted therapy (TT) and compared to patients without targeted therapy (non TT). Actionable targets were identified in all analyzed biopsies. Targeted therapy was administered in nine patients, while eleven received no targeted therapy. No significant difference in risk factors between these two groups was detected. Overall survival (OS) and progression free survival (PFS) were significantly higher in the TT group (OS: P=0.0014, PFS: P=0.0011). Median OS was 8.83 versus 4.93 months and median PFS was 6.17 versus 1.6 months in TT versus non TT group, respectively. QOL did not differ at baseline as well as at four week intervals between the two groups. TT patients had less grade 1 AEs (P=0.009). The frequency of grade 2-4 AEs did not differ. Overall, expression based targeted therapy is a feasible and likely beneficial approach in patients with refractory pediatric sarcomas that warrants further study.